Loading...
•
Dec 31, 2022
Enanta Pharmaceuticals Q1 2023 Earnings Report
Reported financial results for the fiscal first quarter ended December 31, 2022.
Key Takeaways
Enanta Pharmaceuticals reported revenue of $23.6 million for the quarter ended December 31, 2022, primarily from royalty revenue, and a net loss of $29.0 million, or $1.39 per diluted share. The company's cash, cash equivalents, and marketable securities totaled $241.4 million as of December 31, 2022.
Completed enrollment in Phase 2 clinical study of EDP-235 for COVID-19, with topline data expected in May.
Expect Phase 1 data of EDP-323 for Respiratory Syncytial Virus (RSV) in 2Q 2023.
Expanded pipeline with new research programs developing SARS-CoV-2 Papain-Like Protease Inhibitors and Human Metapneumovirus (hMPV)/RSV Dual-Inhibitors.
Revenue for the quarter was $23.6 million.
Enanta Pharmaceuticals
Enanta Pharmaceuticals
Enanta Pharmaceuticals Revenue by Segment
Revenue by Segment
Royalty Revenue
CapyFin.com Forward Guidance
Enanta expects that its current cash, cash equivalents and marketable securities, as well as its continuing royalty revenue, will be sufficient to meet the anticipated cash requirements of its existing business and development programs into the fourth fiscal quarter of 2024.